Bumper Offer - Urjas oil Just @ Rs. 1
Febucip is a prescription drug, available for use as Tablet. Primarily, it is used for the treatment of Gout. The alternative uses of Febucip have also been explained below.
Medical history of the patient along with age and gender determines the dosage of Febucip. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
Some other side effects of Febucip have been listed ahead. Such side effects of Febucip normally do not last long and go away once the treatment is completed. Consult your doctor if these side effects become worse or stay for a longer duration.
Febucip's effect during pregnancy is Severe and Severe while nursing. Warnings related to Febucip's effects on the liver, heart and kidney, if any, have been listed below.
Other contraindications of Febucip have been discussed in the sections ahead.
Drug reaction of Febucip with other medicines has been reported. Refer to the list below for further details.
In addition to these precautions, you may also note that Febucip is safe while driving, and is is addictive in nature.
Febucip is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Febucip is used -
Moderate
Mild
Is the use of Febucip safe for pregnant women?
Febucip should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Febucip safe during breastfeeding?
Febucip may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Febucip on the Kidneys?
There may be some adverse effects on kidney after taking Febucip. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Febucip on the Liver?
Side effects of Febucip rarely affect the liver.
What is the effect of Febucip on the Heart?
You may experience side effects on your heart after taking Febucip. If this happens, then discontinue its use. Consult your medical practitioner, and do as he/she suggests.
Febucip should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Febucip unless your doctor advises you to do so -
Is this Febucip habit forming or addictive?
No, there is no any evidence that Febucip is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Febucip since it does not cause drowsiness.
Is it safe?
Yes, but take Febucip only as per medical advice.
Is it able to treat mental disorders?
No, the use of Febucip in mental disorders is not effective.
Interaction between Food and Febucip
Due to the absence of research, it is difficult to say how Febucip and food will interact.
Interaction between Alcohol and Febucip
No research has been done on this till date. Therefore, it is not known what the effect of taking Febucip with alcohol will be.
This medicine data has been created by -
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 217
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 548-549
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 217
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 548-549
